Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Emergent BioSolutions Inc. on September 22, 2010. The report details a material definitive agreement entered into by Emergent BioDefense Operations Lansing Inc., a wholly-owned subsidiary of the Registrant.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The reported transaction is a no-cost modification to an existing contract.
Material Changes
- Contract Modification: On September 22, 2010, the subsidiary entered into a no-cost modification of a contract dated September 25, 2007, with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services.
- Timeline Extension: The period of performance was extended from September 24, 2010, to December 31, 2010.
- Delivery Schedule: The delivery date for certain specified line items and milestone deliverables related to a post-exposure prophylaxis (PEP) indication for BioThrax® was extended to December 31, 2010.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or new risk factors. The primary focus is the administrative extension of contract performance and delivery dates without additional cost to the government or the company.
Key Facts for Investor Verification
- Verify the impact of the extended delivery date for BioThrax® PEP milestones on future revenue recognition schedules.
- Confirm that the contract modification remains strictly "no-cost" with no hidden obligations or penalties.
- Review the original September 25, 2007 contract terms to understand the full scope of the deliverables now extended to December 31, 2010.